6 completed, 6 terminated, 1 active not recruiting. 6 Phase 1, 6 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Terminated 3 |
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
| Phase 4 | 1 | Active not recruiting 1 |
Follow Farydak: new trials by email Literature Review of Farydak trials Research Report on Farydak
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Abdullah Khan | 1 | 2021-09-27 | 2024-06-06 |
| Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication - Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas | Phase 1 | Terminated | Columbia University | 5 | 2021-07-28 | 2025-06-08 |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG Marizomib, Panobinostat - Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma | Phase 1 | Terminated | Dana-Farber Cancer Institute | 4 | 2020-08-10 | 2024-02-15 |
| A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat Farydak - Multiple Myeloma | Completed | pharmaand GmbH | 248 | 2019-11-04 | 2023-06-15 | |
| Panobinostat Maintenance After HSCT fo High-risk AML and MDS Panobinostat - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Terminated | Goethe University | 52 | 2018-07-24 | 2023-02-16 |
| Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Chemosensitivity Assay, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of Washington | 9 | 2018-02-08 | 2022-05-09 |
| A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Revlimid, Velcade, dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Novartis Pharmaceuticals | 6 | 2016-06-14 | 2018-07-24 |
| Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy Panobinostat, Pegylated Interferon-alpha2a - HIV Infection | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 17 | 2016-05-01 | 2024-02-28 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets - Multiple Myeloma | Phase 2 | Completed | pharmaand GmbH | 248 | 2016-04-27 | 2024-07-12 |
| Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Panobinostat, Sirolimus, Tacrolimus - Graft Versus Host Disease, GVHD | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 42 | 2016-03-04 | 2021-07-21 |
| CINC424A2X01B Rollover Protocol ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 279 | 2015-03-05 | 2026-10-19 |
| Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma Carfilzomib, Panobinostat - Non-Secretory Plasma Cell Myeloma, Plasmacytosis | Phase 1 | Completed | M.D. Anderson Cancer Center | 63 | 2011-07-28 | 2023-09-29 |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma LBH589, bevacizumab - Malignant Glioma | Phase 1 / Phase 2 | Completed | Patrick Y. Wen, MD | 51 | 2009-03-01 | 2017-03-14 |
Multiple Myeloma (6) · Diffuse Intrinsic Pontine Glioma (2) · Graft vs Host Disease (2) · Leukemia, Myeloid, Acute (2) · Recurrence (2) · Bronchiolitis Obliterans Syndrome (1) · Glioma (1) · HIV Infections (1) · Hematologic Diseases (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Thalassemia (1)
Novartis Pharmaceuticals (2) · pharmaand GmbH (2) · Abdullah Khan (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Goethe University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Patrick Y. Wen, MD (1) · University of Washington (1)
United States (11) · Germany (3) · Australia (2) · Belgium (2) · Canada (2) · France (2) · Greece (2) · Hungary (2) · Italy (2) · Lebanon (2) · Netherlands (2) · Poland (2) · Portugal (2) · Russia (2) · South Korea (2)
Abdullah M Khan, MBBS, MSc (1) · Andrew Cowan (1) · Cheng-Chia Wu, MD, PhD (1) · Daniel R Kuritzkes, MD (1) · Gesine Bug, PD Dr. (1) · Katherine Warren, MD (1) · Lia Perez, M.D. (1) · Mathias Lichterfeld, MD, PhD (1) · Patrick Y. Wen, MD (1) · Rajesh T Gandhi, MD (1) · Robert Orlowski (1)
PMID 21984064, PMID 25572329, PMID 33301738, PMID 34242388, PMID 37189240
2014 (1), 2015 (1), P30CA015704 (1), P30CA016672 (1)